Aytu BioPharma, Inc.AYTUNASDAQ
Loading
Revenue Growth Recovery in ProgressRecovering
Percentile Rank54
5Y CAGR-5.2%
Year-over-Year Change
Year-over-year revenue growth rate
5Y CAGR
-5.2%/yr
Long-term compound
Percentile
P54
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 9.19% |
| Q3 2025 | -8.24% |
| Q2 2025 | -17.98% |
| Q1 2025 | 13.75% |
| Q4 2024 | -2.13% |
| Q3 2024 | -7.80% |
| Q2 2024 | 28.17% |
| Q1 2024 | -25.19% |
| Q4 2023 | 5.23% |
| Q3 2023 | -42.02% |
| Q2 2023 | 35.19% |
| Q1 2023 | -13.49% |
| Q4 2022 | -4.98% |
| Q3 2022 | 0.75% |
| Q2 2022 | 13.43% |
| Q1 2022 | 4.64% |
| Q4 2021 | 5.61% |
| Q3 2021 | -6.75% |
| Q2 2021 | 74.16% |
| Q1 2021 | -10.99% |
| Q4 2020 | 12.03% |
| Q3 2020 | -9.02% |
| Q2 2020 | 82.20% |
| Q1 2020 | 156.87% |
| Q4 2019 | 120.53% |
| Q3 2019 | -16.07% |
| Q2 2019 | -27.85% |
| Q1 2019 | 32.47% |
| Q4 2018 | 25.35% |
| Q3 2018 | 54.81% |
| Q2 2018 | 52.39% |
| Q1 2018 | -42.25% |
| Q4 2017 | -2.32% |
| Q3 2017 | 28.73% |
| Q2 2017 | -6.50% |
| Q1 2017 | 12.59% |
| Q4 2016 | 13.75% |
| Q3 2016 | -25.53% |
| Q2 2016 | 40.23% |
| Q1 2016 | 42.39% |